These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 27514589)

  • 1. Langerhans Cell Histiocytosis and Other Histiocytic Diseases of the Lung.
    DeMartino E; Go RS; Vassallo R
    Clin Chest Med; 2016 Sep; 37(3):421-30. PubMed ID: 27514589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mixed histiocytic disorders: Nature versus nurture?
    McClain K; Dimitrion P
    Br J Haematol; 2024 Jul; 205(1):20-21. PubMed ID: 38763166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic Histiocytosis (Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Destombes-Rosai-Dorfman Disease): from Oncogenic Mutations to Inflammatory Disorders.
    Papo M; Cohen-Aubart F; Trefond L; Bauvois A; Amoura Z; Emile JF; Haroche J
    Curr Oncol Rep; 2019 May; 21(7):62. PubMed ID: 31115724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults.
    Milne P; Bigley V; Bacon CM; Néel A; McGovern N; Bomken S; Haniffa M; Diamond EL; Durham BH; Visser J; Hunt D; Gunawardena H; Macheta M; McClain KL; Allen C; Abdel-Wahab O; Collin M
    Blood; 2017 Jul; 130(2):167-175. PubMed ID: 28512190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurological Manifestations of Histiocytic Disorders.
    Banks SA; Sartori Valinotti JC; Go RS; Abeykoon JP; Goyal G; Young JR; Koster MJ; Vassallo R; Ryu JH; Davidge-Pitts CJ; Ravindran A; Bennani NN; Shah MV; Rech KL; Tobin WO;
    Curr Neurol Neurosci Rep; 2023 Jun; 23(6):277-286. PubMed ID: 37209319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1.
    Gatalica Z; Bilalovic N; Palazzo JP; Bender RP; Swensen J; Millis SZ; Vranic S; Von Hoff D; Arceci RJ
    Oncotarget; 2015 Aug; 6(23):19819-25. PubMed ID: 26110571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges in the Histopathologic Diagnosis of Histiocytic Neoplasms.
    Rech KL; He R
    J Natl Compr Canc Netw; 2021 Nov; 19(11):1305-1311. PubMed ID: 34781270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histiocytic disorders: insights into novel biology and implications for therapy of Langerhans cell histiocytosis and Erdheim-Chester disease.
    McClain K
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):395-399. PubMed ID: 33275721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pulmonary histiocytosis: beyond Langerhans cell histiocytosis related to smoking.
    Gallego CT; Bueno J; Cruces E; Stelow EB; Mancheño N; Flors L
    Radiologia (Engl Ed); 2019; 61(3):215-224. PubMed ID: 30686482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dramatic efficacy of dabrafenib in Erdheim-Chester disease (ECD): a pediatric patient with multiple large intracranial ECD lesions hidden by refractory Langerhans cell histiocytosis.
    Hao X; Feng R; Bi Y; Liu Y; Li C; Lu T; Tian Y
    J Neurosurg Pediatr; 2019 Jan; 23(1):48-53. PubMed ID: 30265230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mixed Langerhans Cell Histiocytosis and Erdheim-Chester Disease in a Girl: A Rare and Puzzling Diagnosis.
    Ocak S; Bayramoglu Z; Tugcu D; Karaman S; Unuvar A; Karakas Z
    J Pediatr Hematol Oncol; 2021 Apr; 43(3):e375-e379. PubMed ID: 32097280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Langerhans cell histiocytosis and Erdheim-Chester disease, both with cutaneous presentations, and papillary thyroid carcinoma all harboring the BRAF(V600E) mutation.
    Johnson WT; Patel P; Hernandez A; Grandinetti LM; Huen AC; Marks S; Ho J; Monaco SE; Jaffe R; Picarsic J
    J Cutan Pathol; 2016 Mar; 43(3):270-5. PubMed ID: 26454140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological and clinical significance of somatic mutations in Langerhans cell histiocytosis and related histiocytic neoplastic disorders.
    Allen CE; Parsons DW
    Hematology Am Soc Hematol Educ Program; 2015; 2015():559-64. PubMed ID: 26637772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Combined histiocytosis of the Langerhans group (Langerhans cell histiocytosis and Erdheim-Chester disease) in a 64-year-old man with BRAF and NRAS mutations: a case report].
    Rodríguez-Duque MS; Martín Soler P; González Vela MC; Gómez Román JJ
    Rev Esp Patol; 2023; 56(3):186-190. PubMed ID: 37419557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.
    Diamond EL; Subbiah V; Lockhart AC; Blay JY; Puzanov I; Chau I; Raje NS; Wolf J; Erinjeri JP; Torrisi J; Lacouture M; Elez E; Martínez-Valle F; Durham B; Arcila ME; Ulaner G; Abdel-Wahab O; Pitcher B; Makrutzki M; Riehl T; Baselga J; Hyman DM
    JAMA Oncol; 2018 Mar; 4(3):384-388. PubMed ID: 29188284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highlights of the Management of Adult Histiocytic Disorders: Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Rosai-Dorfman Disease, and Hemophagocytic Lymphohistiocytosis.
    Salama HA; Jazieh AR; Alhejazi AY; Absi A; Alshieban S; Alzahrani M; Alaskar A; Gmati G; Damlaj M; Abuelgasim KA; Alghamdi A; Alahmari B; Almugairi A; Alzahrani H; Bazarbachi A; Musa MOH; Goyal G
    Clin Lymphoma Myeloma Leuk; 2021 Jan; 21(1):e66-e75. PubMed ID: 32943371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Langerhans Cell Histiocytosis and Histiocytic Disorders: A Focus on MAPK Pathway Inhibitors.
    Geerlinks AV; Abla O
    Paediatr Drugs; 2023 Jul; 25(4):399-409. PubMed ID: 37204611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mixed histiocytic neoplasms: A multicentre series revealing diverse somatic mutations and responses to targeted therapy.
    Friedman JS; Durham BH; Reiner AS; Yabe M; Petrova-Drus K; Dogan A; Pulitzer M; Busam KJ; Francis JH; Rampal RK; Ulaner GA; Reddy R; Yeh R; Hatzoglou V; Lacouture ME; Rotemberg V; Mazor RD; Hershkovitz-Rokah O; Shpilberg O; Goyal G; Go RS; Abeykoon JP; Rech K; Morlote D; Fidai S; Gannamani V; Zia M; Abdel-Wahab O; Panageas KS; Rosenblum MK; Diamond EL
    Br J Haematol; 2024 Jul; 205(1):127-137. PubMed ID: 38613141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MAP2K1-driven mixed Langerhans cell histiocytosis, Rosai-Dorfman-Destombes disease and Erdheim-Chester disease, clonally related to acute myeloid leukemia.
    Bonometti A; Ferrario G; Parafioriti A; Giardino D; Simonetti F; Ginori A; Passoni E; Berti E;
    J Cutan Pathol; 2021 May; 48(5):637-643. PubMed ID: 33188581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Mayo Clinic Histiocytosis Working Group Consensus Statement for the Diagnosis and Evaluation of Adult Patients With Histiocytic Neoplasms: Erdheim-Chester Disease, Langerhans Cell Histiocytosis, and Rosai-Dorfman Disease.
    Goyal G; Young JR; Koster MJ; Tobin WO; Vassallo R; Ryu JH; Davidge-Pitts CJ; Hurtado MD; Ravindran A; Sartori Valinotti JC; Bennani NN; Shah MV; Rech KL; Go RS;
    Mayo Clin Proc; 2019 Oct; 94(10):2054-2071. PubMed ID: 31472931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.